HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.

AbstractOBJECTIVE:
To determine the efficacy of various intravenous immunoglobulin (IVIG) protocols used in the treatment of autoimmune and chronic inflammatory disorders.
DATA SOURCES:
Literature retrieval was accessed through MEDLINE (November 1984-March 2007) and a search was conducted using the term intravenous immunoglobulin. References cited in the selected articles were also reviewed.
STUDY SELECTION AND DATA EXTRACTION:
Inclusion criteria for studies were (1) English language, (2) randomized controlled trials, (3) defined protocols, (4) a minimum of 15 patients, and (5) objective criteria provided to assess clinical outcomes and course.
DATA SYNTHESIS:
The therapeutic efficacy of IVIG therapy is well established, and defined protocols exist for treatment of Kawasaki disease, immune thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and autoimmune mucocutaneous blistering diseases. In the absence of a defined protocol, studies have demonstrated that IVIG therapy is effective in the treatment of myasthenia gravis, dermatomyositis, stiff person syndrome, antineutrophil cytoplasmic antibody positive systemic vasculitides, Graves' ophthalmopathy, and certain forms of systemic lupus erythematosus. It might also be of benefit in some patients with relapsing-remitting multiple sclerosis. The outcomes are variable in these studies. In toxic epidermal necrolysis and Stevens-Johnson syndrome, use of IVIG has dramatically influenced clinical response and reduced mortality.
CONCLUSIONS:
The cumulative evidence suggests that the clinical outcomes observed are significantly influenced by the use of a defined protocol. There is a need for multicenter trials approved by the Food and Drug Administration to better define the role of IVIG in many disease states. Such studies would be able to establish the indications for use, optimal dose, frequency of infusions, duration of therapy, and need for gradual withdrawal versus sudden cessation. Defined protocols resulting from the study of a large cohort of patients often convince insurance companies to create policies that provide access to IVIG therapy.
AuthorsHakan M Gürcan, A Razzaque Ahmed
JournalThe Annals of pharmacotherapy (Ann Pharmacother) Vol. 41 Issue 5 Pg. 812-23 (May 2007) ISSN: 1542-6270 [Electronic] United States
PMID17440006 (Publication Type: Journal Article, Review)
Chemical References
  • Immunoglobulins, Intravenous
  • Immunologic Factors
Topics
  • Autoimmune Diseases (drug therapy)
  • Humans
  • Immunoglobulins, Intravenous (adverse effects, therapeutic use)
  • Immunologic Factors (adverse effects, therapeutic use)
  • Inflammation (drug therapy)
  • Randomized Controlled Trials as Topic
  • Skin Diseases (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: